Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi-Center Study in Patients With Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DCR-PHXC Solution for Injection (Subcutaneous Use)

Trial Profile

A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi-Center Study in Patients With Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DCR-PHXC Solution for Injection (Subcutaneous Use)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nedosiran (Primary)
  • Indications Primary hyperoxaluria; Primary hyperoxaluria type 1
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
  • Acronyms PHYOX; PHYOX1
  • Sponsors Dicerna Pharmaceuticals
  • Most Recent Events

    • 01 Mar 2022 Results assessing safety, pharmacokinetics, pharmacodynamics, and exposure-response of subcutaneous nedosiran published in the Kidney International
    • 04 Jan 2021 According to a Dicerna Pharmaceuticals media release, data from PHYOX1, PHYOX2, PHYOX4, the ongoing PHYOX3 open-label extension study, and the PHYOX-OBX natural history study of PH3 participants, are expected to form the basis of the nedosiran New Drug Application (NDA) submission in the third quarter of 2021.
    • 06 Aug 2020 Interim results presented in the Dicerna Pharmaceuticals Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top